Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell. (3rd March 2022)
- Record Type:
- Journal Article
- Title:
- Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell. (3rd March 2022)
- Main Title:
- Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell
- Authors:
- Romecín, Paola Alejandra
Vinyoles, Meritxell
López-Millán, Belén
de la Guardia, Rafael Diaz
Atucha, Noemi M
Querol, Sergi
Bueno, Clara
Benitez, Raquel
Gonzalez-Rey, Elena
Delgado, Mario
Menéndez, Pablo - Abstract:
- Abstract: Mesenchymal stromal stem/cells (MSC) therapies are clinically used in a wide range of disorders based on their robust HLA-independent immunosuppressive and anti-inflammatory properties. However, the mechanisms underlying MSC therapeutic activity remain elusive as demonstrated by the unpredictable therapeutic efficacy of MSC infusions reported in multiple clinical trials. A seminal recent study showed that infused MSCs are actively induced to undergo apoptosis by recipient cytotoxic T cells, a mechanism that triggers in vivo recipient-induced immunomodulation by such apoptotic MSCs, and the need for such recipient cytotoxic cell activity could be replaced by the administration of ex vivo-generated apoptotic MSCs. Moreover, the use of MSC-derived extracellular vesicles (MSC-EVs) is being actively explored as a cell-free therapeutic alternative over the parental MSCs. We hypothesized that the introduction of a "suicide gene" switch into MSCs may offer on-demand in vivo apoptosis of transplanted MSCs. Here, we prompted to investigate the utility of the iCasp9/AP1903 suicide gene system in inducing apoptosis of MSCs. iCasp9/AP1903-induced apoptotic MSCs (MSC iCasp9+ ) were tested in vitro and in in vivo models of acute colitis. Our data show a very similar and robust immunosuppressive and anti-inflammatory properties of both "parental" alive MSC GFP+ cells and apoptotic MSC iCasp9+ cells in vitro and in vivo regardless of whether apoptosis was induced in vivo or inAbstract: Mesenchymal stromal stem/cells (MSC) therapies are clinically used in a wide range of disorders based on their robust HLA-independent immunosuppressive and anti-inflammatory properties. However, the mechanisms underlying MSC therapeutic activity remain elusive as demonstrated by the unpredictable therapeutic efficacy of MSC infusions reported in multiple clinical trials. A seminal recent study showed that infused MSCs are actively induced to undergo apoptosis by recipient cytotoxic T cells, a mechanism that triggers in vivo recipient-induced immunomodulation by such apoptotic MSCs, and the need for such recipient cytotoxic cell activity could be replaced by the administration of ex vivo-generated apoptotic MSCs. Moreover, the use of MSC-derived extracellular vesicles (MSC-EVs) is being actively explored as a cell-free therapeutic alternative over the parental MSCs. We hypothesized that the introduction of a "suicide gene" switch into MSCs may offer on-demand in vivo apoptosis of transplanted MSCs. Here, we prompted to investigate the utility of the iCasp9/AP1903 suicide gene system in inducing apoptosis of MSCs. iCasp9/AP1903-induced apoptotic MSCs (MSC iCasp9+ ) were tested in vitro and in in vivo models of acute colitis. Our data show a very similar and robust immunosuppressive and anti-inflammatory properties of both "parental" alive MSC GFP+ cells and apoptotic MSC iCasp9+ cells in vitro and in vivo regardless of whether apoptosis was induced in vivo or in vitro before administering MSC iCasp9+ lysates. This development of an efficient iCasp9 switch may potentiate the safety of MSC-based therapies in the case of an adverse event and, will also circumvent current logistic technical limitations and biological uncertainties associated to MSC-EVs. Graphical Abstract: … (more)
- Is Part Of:
- Stem cells translational medicine. Volume 11:Number 1(2022)
- Journal:
- Stem cells translational medicine
- Issue:
- Volume 11:Number 1(2022)
- Issue Display:
- Volume 11, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 11
- Issue:
- 1
- Issue Sort Value:
- 2022-0011-0001-0000
- Page Start:
- 88
- Page End:
- 96
- Publication Date:
- 2022-03-03
- Subjects:
- BM-MSC -- WJ-MSC -- iCasp9 switch -- immunosuppression -- anti-inflammatory -- colitis in vivo model
Stem cells -- Periodicals
Regenerative medicine -- Periodicals
Periodicals
616.0277405 - Journal URLs:
- https://academic.oup.com/stcltm ↗
http://stemcellsjournals.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2157-6580/issues/ ↗
http://stemcellstm.alphamedpress.org/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1093/stcltm/szab007 ↗
- Languages:
- English
- ISSNs:
- 2157-6564
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20741.xml